NEDOCROMIL SODIUM

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H15NO7.2Na
Molecular Weight	415.3044
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].CCCC1=C2OC(=CC(=O)C2=CC3=C1N(CC)C(=CC3=O)C([O-])=O)C([O-])=O

InChI

InChIKey=JQEKDNLKIVGXAU-UHFFFAOYSA-L

InChI=1S/C19H17NO7.2Na/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11;;/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H15NO7
Molecular Weight	369.3249
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021009s010lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00716 | https://www.drugs.com/ppa/nedocromil-sodium.html | http://reference.medscape.com/drug/alocril-nedocromil-ophthalmic-999594

Nedocromil is a medication considered as mast cell stabilizer used to treat itching associated with allergic conjunctivitis. Nedocromil has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Nedocromil inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-geneñrelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Nedocromil does not possess any bronchodilator, antihistamine, or corticosteroid activity. Nedocromil is indicated for the treatment of itching associated with allergic conjunctivitis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
eosinophil chemotaxis 6 Target ID: GO:0048245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9150324	Inhibitor 8297
mast cell degranulation 7 Target ID: GO:0043303 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26803520	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Itching associated with allergic conjunctivitis 5 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021009s010lbl.pdf	Primary		Approved 8429	TILADE Approved Use ALOCRIL ® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. Launch Date 7.2567357E11
Asthma 241 Sources: https://www.drugs.com/ppa/nedocromil-sodium.html	Primary		Approved 8429	TILADE Approved Use ALOCRIL ® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. Launch Date 7.2567357E11

C_max

Value	Dose	Analyte	Population
13.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	6 μg/kg bw single, intravenous dose: 6 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.1 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.6 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	20 mg single, respiratory dose: 20 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.4 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
10.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	6 μg/kg bw single, intravenous dose: 6 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4.6 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
49.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6.2 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	20 mg single, respiratory dose: 20 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.9 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
21.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	70.5 mg single, oral dose: 70.5 mg route of administration: Oral experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2825746/	4 mg single, respiratory dose: 4 mg route of administration: Respiratory experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
31.6 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf	0.42 mg single, intravenous dose: 0.42 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NEDOCROMIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957	unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957	Disc. AE: Eyeball itching, Swelling... AEs leading to discontinuation/dose reduction: Eyeball itching Swelling Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957

AEs

AE	Significance	Dose	Population
Eyeball itching	Disc. AE	2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957	unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957
Swelling	Disc. AE	2 % 2 times / day multiple, ophthalmic Highest studied dose Dose: 2 %, 2 times / day Route: ophthalmic Route: multiple Dose: 2 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957	unhealthy, 12-61 n = 289 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: 12-61 Sex: M+F Population Size: 289 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf Page: CR 1957

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270 UGT 192

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021009s010lbl.pdf#page=1 Page: 1.0	no
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021009s010lbl.pdf#page=1 Page: 1.0	no

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7492	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7492
ChemicalBook	CB9122310	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9122310
MolPort	MolPort-006-167-614	https://www.molport.com/shop/molecule-link/MolPort-006-167-614
ZINC	ZINC000003782807	http://zinc15.docking.org/substances/ZINC000003782807

PubMed

Title	Date	PubMed
Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers.	1992 Oct	1329582
Spotlight on montelukast in asthma in children 2 to 14 years of age.	2002	14720060
[Nedocromil sodium--the influence on allergic inflammation].	2002	12182006
[IL-10 serum levels in children with moderate asthma].	2002	12148173
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].	2002 Aug 5	12162793
[Exhaled nitric oxide in healthy and asthmatic children].	2002 Jul	12139887
Asthma: knowledge and practice patterns of Louisiana family physicians.	2002 May-Jun	12139358
[For the family physician allergy season is all year long. Strategies against running noses].	2002 Nov 7	12534052
Allergen challenge and deposition of nedocromil sodium in asthma.	2002 Winter	12581508
Antiasthmatic effects of nedocromil sodium.	2003	15168867
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].	2003 Apr	12843888
A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.	2003 Apr	12809959
Corneal flap complications in refractive surgery: Part 2: postoperative treatments of diffuse lamellar keratitis in an experimental animal model.	2003 Apr	12686253
Minimizing attrition in a long-term clinical trial of pediatric asthma.	2003 Aug	12952111
Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial.	2003 Aug	12859551
Immune response to hepatitis B vaccine in asthmatic children.	2003 Dec	14618645
A review of once-daily delivery of anti-asthmatic drugs in children.	2003 Feb	12603705
Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study.	2003 Jan-Feb	12772816
A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.	2003 Jul	12946546
Model-free treatment of the dehydration kinetics of nedocromil sodium trihydrate.	2003 Jul	12820141
Asthma and other wheezing disorders of childhood.	2003 Jun	15366138
Supplementation of fexofenadine therapy with nedocromil sodium 2% ophthalmic solution to treat ocular symptoms of seasonal allergic conjunctivitis.	2003 Jun	12786770
Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma.	2003 Jun	12777589
Treatment compliance, passive smoking, and asthma control: a three year cohort study.	2003 Mar	12598385
Arterial hypoxemia in exercising thoroughbreds is not affected by pre-exercise nedocromil sodium inhalation.	2003 Mar 3	12609481
Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma.	2003 May	12756375
Severe acute respiratory syndrome, a pathological immune response to the new coronavirus--implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology.	2004	15671750
Single-dose agents in the prevention of exercise-induced asthma: a descriptive review.	2004	15658883
Inhaled cromones for prolonged non-specific cough in children.	2004	15106252
Sensitivity analysis of longitudinal normal data with drop-outs.	2004 Apr 15	15057877
Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study.	2004 Aug	15305946
Progression of asthma measured by lung function in the childhood asthma management program.	2004 Aug 1	15028558
[Strategies for the prevention and treatment of allergies in children and adolescents].	2004 Dec 9	15658520
Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome.	2004 Feb	14975042
Evaluation of preoperative and postoperative prophylactic regimens for prevention and treatment of diffuse lamellar keratitis.	2004 Jan	14967290
Evidence-based asthma management.	2004 Jul	15222910
Asthma and other wheezing disorders in infants and children.	2004 Jun	15652008
Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.	2004 Jun	15186569
Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma.	2004 Jun	15173493
Investigation into the mechanisms by which nedocromil sodium, frusemide and bumetanide inhibit the histamine-induced itch and flare response in human skin in vivo.	2004 Mar	15005740
Disodium cromoglycate suppresses the induction of cysteinyl leukotriene synthesis during granulocytic differentiation in HL-60 cells.	2004 Mar	15002759
Clinical inquiries. Is nedocromil effective in preventing asthmatic attacks in patients with asthma?	2004 Nov	15527735
Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats.	2004 Nov	15231495
Safety and application of induced sputum analysis in childhood asthma.	2004 Sep	15356559
Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.	2005	15631542
The management of asthma and rhinitis during pregnancy.	2005 Apr	15857273
Respiratory morbidity in office workers in a water-damaged building.	2005 Apr	15811840
Asthma controller therapy during pregnancy.	2005 Feb	15695974
Polymorphisms in signal transducer and activator of transcription 3 and lung function in asthma.	2005 Jun 3	15935090
Childhood asthma: treatment update.	2005 May 15	15926412

Patents

Sample Use Guides

In Vivo Use Guide

Instill 1-2 gtt in each eye twice daily throughout time of exposure (ie, until pollen season is over or offending allergen terminated)

Route of Administration: Topical

In Vitro Use Guide

Eosinophil chemotaxis was studied using a modified Boyden chamber technique. Sets of six chambers each were set up to investigate different experimental conditions. Half a millilitre of either medium 199, conditioned medium, or conditioned medium containing 10^-7, 10^-6 or 10^-5 M nedocromil sodium, was placed in the lower compartment of each chamber, and incubated for 90 min at 37°C in the presence of 2510^3 eosinophils in the upper compartment, separated by an 8 m pore size microporous polycarbonate membrane. At the end of incubation, the membrane was removed, fixed in absolute alcohol for 5 min and then washed under running tap water for 1 min. The membrane was stained with Chromotrope R for 5 min. The stained membrane was dehydrated in absolute alcohol for 5 min, cleared in CNP 30 reagent (BDH LaboratorySupplies, Lutterworth, UK), and then mounted in Styrolite™ mounting medium. The membrane was immediately examined by light microscopy, and the number of eosinophils coming through to the other side of the membrane was counted in 10 random high power fields (HPF) at x40 magnification.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:03:43 UTC 2023` Edited by `admin` on `Fri Dec 15 16:03:43 UTC 2023`
Record UNII	ET8IF4KS1T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEDOCROMIL SODIUM

Official Name

English

NEDOCROMIL DISODIUM SALT

Common Name

English

FPL-59002KP

Code

English

RAPITIL

Brand Name

English

NEDOCROMIL SODIUM [MART.]

Common Name

English

NEDOCROMIL SODIUM [VANDF]

Common Name

English

Nedocromil sodium [WHO-DD]

Common Name

English

NEDOCROMIL DISODIUM SALT [MI]

Common Name

English

FPL 59002KP

Code

English

NEDOCROMIL SODIUM [ORANGE BOOK]

Common Name

English

4H-PYRANO(3,2-G)QUINOLINE-2,8-DICARBOXYLIC ACID, 9-ETHYL-6,9-DIHYDRO-4,6-DIOXO-10-PROPYL-, SODIUM SALT (1:2)

Systematic Name

English

ALOCRIL

Brand Name

English

NEDOCROMIL SODIUM [USAN]

Common Name

English

TILARIN

Brand Name

English

4H-PYRANO(3,2-G)QUINOLINE-2,8-DICARBOXYLIC ACID, 9-ETHYL-6,9-DIHYDRO-4,6-DIOXO-10-PROPYL-, DISODIUM SALT

Common Name

English

TAYLED

Brand Name

English

TILADE

Brand Name

English

NEDOCROMIL SODIUM [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257